Evaluation of kidney function tests in HIV‐positive patients receiving combined antiretroviral therapy
Introduction Human immunodeficiency virus is a chronic infection that attacks the immune system of the human body, particularly CD4 T lymphocytes. Combined antiretroviral therapies are highly effective in virological suppression of human immunodeficiency virus infection. It has been shown that some...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical practice (Esher) 2021-08, Vol.75 (8), p.e14542-n/a |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 8 |
| container_start_page | e14542 |
| container_title | International journal of clinical practice (Esher) |
| container_volume | 75 |
| creator | Aydin, Emre Yilmaz Aydin, Fatma Demir, Yakup Yildirim, Yasar Celen, Mustafa Kemal |
| description | Introduction
Human immunodeficiency virus is a chronic infection that attacks the immune system of the human body, particularly CD4 T lymphocytes. Combined antiretroviral therapies are highly effective in virological suppression of human immunodeficiency virus infection. It has been shown that some retroviral therapies have a higher nephrotoxicity potential. As a result of renal injury, serum creatinine increases and the estimated glomerular filtration rate is reduced. The aim of our study was to assess changes in kidney function during a 24‐month period in HIV‐positive patients who were begun on combined antiretroviral therapy.
Material and Methods
A total of 127 HIV‐positive patients were enrolled. The patients were divided into five groups; patients who received no therapy were designated as group 1; those who received Dolutegravir/Abacavir/Lamivudine combination as group 2; those who received Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate combination as group 3; those who received Emtricitabine/Tenofovir Disoproxil Fumarate/Dolutegravir combination as group 4; and those who received Emtricitabine/Tenofovir Disoproxil Fumarate/Raltegravir combination as group 5. We compared the effects of these drugs on estimated glomerular filtration rate during a 24‐month follow‐up period.
Results
At the 24th month of therapy, a significant difference was observed between the estimated glomerular filtration rate (eGFR) levels of the study groups (P |
| doi_str_mv | 10.1111/ijcp.14542 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2542357199</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2542357199</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3702-34ad8cde659558ba4f67f2d204d826aa5dabb090b12759284238f1bb14a56ba23</originalsourceid><addsrcrecordid>eNp9kE1OwzAQhS0EEqWw4QSW2CCkFP_mZ4mqQosqwQLYRo7jUJfUDnYSlB1H4IycBLdlxYLZzGjme6OnB8A5RhMc6lqvZTPBjDNyAEY4YSTChOHDMNM4jTii-BiceL9GiHCeohFYzXpRd6LV1kBbwTddGjXAqjNyt2qVbz3UBs4XL9-fX431utW9gk1QKBNOTkmle21eobSbQhtVQmFa7VTrbK-dqGG7Uk40wyk4qkTt1dlvH4Pn29nTdB4tH-4W05tlJGmCSESZKFNZqphnwWAhWBUnFSkJYmVKYiF4KYoCZajAJOEZSRmhaYWLAjPB40IQOgaX-7-Ns-9dsJ9vtJeqroVRtvM5CdlQnuAsC-jFH3RtO2eCu0BxylgwQQN1taeks947VeWN0xvhhhyjfBt6vg0934UeYLyHP3Sthn_IfHE_fdxrfgDPHYZp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2553446593</pqid></control><display><type>article</type><title>Evaluation of kidney function tests in HIV‐positive patients receiving combined antiretroviral therapy</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Aydin, Emre ; Yilmaz Aydin, Fatma ; Demir, Yakup ; Yildirim, Yasar ; Celen, Mustafa Kemal</creator><creatorcontrib>Aydin, Emre ; Yilmaz Aydin, Fatma ; Demir, Yakup ; Yildirim, Yasar ; Celen, Mustafa Kemal</creatorcontrib><description><![CDATA[Introduction
Human immunodeficiency virus is a chronic infection that attacks the immune system of the human body, particularly CD4 T lymphocytes. Combined antiretroviral therapies are highly effective in virological suppression of human immunodeficiency virus infection. It has been shown that some retroviral therapies have a higher nephrotoxicity potential. As a result of renal injury, serum creatinine increases and the estimated glomerular filtration rate is reduced. The aim of our study was to assess changes in kidney function during a 24‐month period in HIV‐positive patients who were begun on combined antiretroviral therapy.
Material and Methods
A total of 127 HIV‐positive patients were enrolled. The patients were divided into five groups; patients who received no therapy were designated as group 1; those who received Dolutegravir/Abacavir/Lamivudine combination as group 2; those who received Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate combination as group 3; those who received Emtricitabine/Tenofovir Disoproxil Fumarate/Dolutegravir combination as group 4; and those who received Emtricitabine/Tenofovir Disoproxil Fumarate/Raltegravir combination as group 5. We compared the effects of these drugs on estimated glomerular filtration rate during a 24‐month follow‐up period.
Results
At the 24th month of therapy, a significant difference was observed between the estimated glomerular filtration rate (eGFR) levels of the study groups (P < .001). eGFR level was significantly higher in group 4 compared with groups 1, 2 and 3 (P = .009, P < .001, P < .001, respectively), whereas it was significantly lower in group 5 than groups 1, 2 and 3 (P = .005, P < .001, P < .001, respectively). No significant eGFR difference was found between group 4 and group 5 (P > .05). Serum creatinine level was significantly higher in groups 4 and 5 compared with the other groups (P < .001).
Conclusion
The use of TDF‐containing regimens causes renal dysfunction. Therefore, we recommend close monitoring of renal function, especially in patients treated with TDF.]]></description><identifier>ISSN: 1368-5031</identifier><identifier>EISSN: 1742-1241</identifier><identifier>DOI: 10.1111/ijcp.14542</identifier><language>eng</language><publisher>London: Hindawi Limited</publisher><subject>Abacavir ; Antiretroviral drugs ; Antiretroviral therapy ; CD4 antigen ; Chronic infection ; Creatinine ; Drug therapy ; Emtricitabine ; Epidermal growth factor receptors ; Glomerular filtration rate ; HIV ; Human immunodeficiency virus ; Immune system ; Immunosuppressive agents ; Kidneys ; Lamivudine ; Lymphocytes T ; Renal function ; Tenofovir</subject><ispartof>International journal of clinical practice (Esher), 2021-08, Vol.75 (8), p.e14542-n/a</ispartof><rights>2021 John Wiley & Sons Ltd</rights><rights>Copyright © 2021 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3702-34ad8cde659558ba4f67f2d204d826aa5dabb090b12759284238f1bb14a56ba23</citedby><cites>FETCH-LOGICAL-c3702-34ad8cde659558ba4f67f2d204d826aa5dabb090b12759284238f1bb14a56ba23</cites><orcidid>0000-0001-5876-2241 ; 0000-0001-7657-3065 ; 0000-0001-5424-5714 ; 0000-0002-8101-2497 ; 0000-0003-2419-3436</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fijcp.14542$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fijcp.14542$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids></links><search><creatorcontrib>Aydin, Emre</creatorcontrib><creatorcontrib>Yilmaz Aydin, Fatma</creatorcontrib><creatorcontrib>Demir, Yakup</creatorcontrib><creatorcontrib>Yildirim, Yasar</creatorcontrib><creatorcontrib>Celen, Mustafa Kemal</creatorcontrib><title>Evaluation of kidney function tests in HIV‐positive patients receiving combined antiretroviral therapy</title><title>International journal of clinical practice (Esher)</title><description><![CDATA[Introduction
Human immunodeficiency virus is a chronic infection that attacks the immune system of the human body, particularly CD4 T lymphocytes. Combined antiretroviral therapies are highly effective in virological suppression of human immunodeficiency virus infection. It has been shown that some retroviral therapies have a higher nephrotoxicity potential. As a result of renal injury, serum creatinine increases and the estimated glomerular filtration rate is reduced. The aim of our study was to assess changes in kidney function during a 24‐month period in HIV‐positive patients who were begun on combined antiretroviral therapy.
Material and Methods
A total of 127 HIV‐positive patients were enrolled. The patients were divided into five groups; patients who received no therapy were designated as group 1; those who received Dolutegravir/Abacavir/Lamivudine combination as group 2; those who received Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate combination as group 3; those who received Emtricitabine/Tenofovir Disoproxil Fumarate/Dolutegravir combination as group 4; and those who received Emtricitabine/Tenofovir Disoproxil Fumarate/Raltegravir combination as group 5. We compared the effects of these drugs on estimated glomerular filtration rate during a 24‐month follow‐up period.
Results
At the 24th month of therapy, a significant difference was observed between the estimated glomerular filtration rate (eGFR) levels of the study groups (P < .001). eGFR level was significantly higher in group 4 compared with groups 1, 2 and 3 (P = .009, P < .001, P < .001, respectively), whereas it was significantly lower in group 5 than groups 1, 2 and 3 (P = .005, P < .001, P < .001, respectively). No significant eGFR difference was found between group 4 and group 5 (P > .05). Serum creatinine level was significantly higher in groups 4 and 5 compared with the other groups (P < .001).
Conclusion
The use of TDF‐containing regimens causes renal dysfunction. Therefore, we recommend close monitoring of renal function, especially in patients treated with TDF.]]></description><subject>Abacavir</subject><subject>Antiretroviral drugs</subject><subject>Antiretroviral therapy</subject><subject>CD4 antigen</subject><subject>Chronic infection</subject><subject>Creatinine</subject><subject>Drug therapy</subject><subject>Emtricitabine</subject><subject>Epidermal growth factor receptors</subject><subject>Glomerular filtration rate</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Immune system</subject><subject>Immunosuppressive agents</subject><subject>Kidneys</subject><subject>Lamivudine</subject><subject>Lymphocytes T</subject><subject>Renal function</subject><subject>Tenofovir</subject><issn>1368-5031</issn><issn>1742-1241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kE1OwzAQhS0EEqWw4QSW2CCkFP_mZ4mqQosqwQLYRo7jUJfUDnYSlB1H4IycBLdlxYLZzGjme6OnB8A5RhMc6lqvZTPBjDNyAEY4YSTChOHDMNM4jTii-BiceL9GiHCeohFYzXpRd6LV1kBbwTddGjXAqjNyt2qVbz3UBs4XL9-fX431utW9gk1QKBNOTkmle21eobSbQhtVQmFa7VTrbK-dqGG7Uk40wyk4qkTt1dlvH4Pn29nTdB4tH-4W05tlJGmCSESZKFNZqphnwWAhWBUnFSkJYmVKYiF4KYoCZajAJOEZSRmhaYWLAjPB40IQOgaX-7-Ns-9dsJ9vtJeqroVRtvM5CdlQnuAsC-jFH3RtO2eCu0BxylgwQQN1taeks947VeWN0xvhhhyjfBt6vg0934UeYLyHP3Sthn_IfHE_fdxrfgDPHYZp</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Aydin, Emre</creator><creator>Yilmaz Aydin, Fatma</creator><creator>Demir, Yakup</creator><creator>Yildirim, Yasar</creator><creator>Celen, Mustafa Kemal</creator><general>Hindawi Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5876-2241</orcidid><orcidid>https://orcid.org/0000-0001-7657-3065</orcidid><orcidid>https://orcid.org/0000-0001-5424-5714</orcidid><orcidid>https://orcid.org/0000-0002-8101-2497</orcidid><orcidid>https://orcid.org/0000-0003-2419-3436</orcidid></search><sort><creationdate>202108</creationdate><title>Evaluation of kidney function tests in HIV‐positive patients receiving combined antiretroviral therapy</title><author>Aydin, Emre ; Yilmaz Aydin, Fatma ; Demir, Yakup ; Yildirim, Yasar ; Celen, Mustafa Kemal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3702-34ad8cde659558ba4f67f2d204d826aa5dabb090b12759284238f1bb14a56ba23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Abacavir</topic><topic>Antiretroviral drugs</topic><topic>Antiretroviral therapy</topic><topic>CD4 antigen</topic><topic>Chronic infection</topic><topic>Creatinine</topic><topic>Drug therapy</topic><topic>Emtricitabine</topic><topic>Epidermal growth factor receptors</topic><topic>Glomerular filtration rate</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Immune system</topic><topic>Immunosuppressive agents</topic><topic>Kidneys</topic><topic>Lamivudine</topic><topic>Lymphocytes T</topic><topic>Renal function</topic><topic>Tenofovir</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aydin, Emre</creatorcontrib><creatorcontrib>Yilmaz Aydin, Fatma</creatorcontrib><creatorcontrib>Demir, Yakup</creatorcontrib><creatorcontrib>Yildirim, Yasar</creatorcontrib><creatorcontrib>Celen, Mustafa Kemal</creatorcontrib><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical practice (Esher)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aydin, Emre</au><au>Yilmaz Aydin, Fatma</au><au>Demir, Yakup</au><au>Yildirim, Yasar</au><au>Celen, Mustafa Kemal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of kidney function tests in HIV‐positive patients receiving combined antiretroviral therapy</atitle><jtitle>International journal of clinical practice (Esher)</jtitle><date>2021-08</date><risdate>2021</risdate><volume>75</volume><issue>8</issue><spage>e14542</spage><epage>n/a</epage><pages>e14542-n/a</pages><issn>1368-5031</issn><eissn>1742-1241</eissn><abstract><![CDATA[Introduction
Human immunodeficiency virus is a chronic infection that attacks the immune system of the human body, particularly CD4 T lymphocytes. Combined antiretroviral therapies are highly effective in virological suppression of human immunodeficiency virus infection. It has been shown that some retroviral therapies have a higher nephrotoxicity potential. As a result of renal injury, serum creatinine increases and the estimated glomerular filtration rate is reduced. The aim of our study was to assess changes in kidney function during a 24‐month period in HIV‐positive patients who were begun on combined antiretroviral therapy.
Material and Methods
A total of 127 HIV‐positive patients were enrolled. The patients were divided into five groups; patients who received no therapy were designated as group 1; those who received Dolutegravir/Abacavir/Lamivudine combination as group 2; those who received Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate combination as group 3; those who received Emtricitabine/Tenofovir Disoproxil Fumarate/Dolutegravir combination as group 4; and those who received Emtricitabine/Tenofovir Disoproxil Fumarate/Raltegravir combination as group 5. We compared the effects of these drugs on estimated glomerular filtration rate during a 24‐month follow‐up period.
Results
At the 24th month of therapy, a significant difference was observed between the estimated glomerular filtration rate (eGFR) levels of the study groups (P < .001). eGFR level was significantly higher in group 4 compared with groups 1, 2 and 3 (P = .009, P < .001, P < .001, respectively), whereas it was significantly lower in group 5 than groups 1, 2 and 3 (P = .005, P < .001, P < .001, respectively). No significant eGFR difference was found between group 4 and group 5 (P > .05). Serum creatinine level was significantly higher in groups 4 and 5 compared with the other groups (P < .001).
Conclusion
The use of TDF‐containing regimens causes renal dysfunction. Therefore, we recommend close monitoring of renal function, especially in patients treated with TDF.]]></abstract><cop>London</cop><pub>Hindawi Limited</pub><doi>10.1111/ijcp.14542</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-5876-2241</orcidid><orcidid>https://orcid.org/0000-0001-7657-3065</orcidid><orcidid>https://orcid.org/0000-0001-5424-5714</orcidid><orcidid>https://orcid.org/0000-0002-8101-2497</orcidid><orcidid>https://orcid.org/0000-0003-2419-3436</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1368-5031 |
| ispartof | International journal of clinical practice (Esher), 2021-08, Vol.75 (8), p.e14542-n/a |
| issn | 1368-5031 1742-1241 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2542357199 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Abacavir Antiretroviral drugs Antiretroviral therapy CD4 antigen Chronic infection Creatinine Drug therapy Emtricitabine Epidermal growth factor receptors Glomerular filtration rate HIV Human immunodeficiency virus Immune system Immunosuppressive agents Kidneys Lamivudine Lymphocytes T Renal function Tenofovir |
| title | Evaluation of kidney function tests in HIV‐positive patients receiving combined antiretroviral therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T00%3A40%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20kidney%20function%20tests%20in%20HIV%E2%80%90positive%20patients%20receiving%20combined%20antiretroviral%20therapy&rft.jtitle=International%20journal%20of%20clinical%20practice%20(Esher)&rft.au=Aydin,%20Emre&rft.date=2021-08&rft.volume=75&rft.issue=8&rft.spage=e14542&rft.epage=n/a&rft.pages=e14542-n/a&rft.issn=1368-5031&rft.eissn=1742-1241&rft_id=info:doi/10.1111/ijcp.14542&rft_dat=%3Cproquest_cross%3E2542357199%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2553446593&rft_id=info:pmid/&rfr_iscdi=true |